Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Predicting Outcomes in Younger Patients with AML
Haematologica; 2017 Aug; Papaioannou, et al
Long non-coding RNA profiling carries predictive value in younger adults with acute myeloid leukemia (AML), according to a study involving more than 400 individuals.
Participants were <60 years of age and had newly-diagnosed cytogenetically normal AML. Investigators performed whole transcriptome profiling in training (n=263) and validation (n=114) sets. They derived a prognostic score from the training set using 24 long non-coding RNAs linked with event-free survival. Among the results in the validation cohort:
- Patients with high scores had shorter disease-free, overall, and event-free survival than those with low scores.
- Long non-coding RNA score status independently predicted disease-free and event-free survival.
- Only double CEBPA and NPM1 mutations, as well as FLT3-ITD, were linked with distinct long non-coding RNA signatures.
- Correlating long non-coding RNA scores with messenger RNA and microRNA expression identified enrichment of genes involved in lymphocyte/leukocyte activation, inflammation, and apoptosis in patients with high scores.
Papaioannou, D, Nicolet D, Volinia, S, et al. Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica. 2017;102:1391-1400. doi:10.3324/haematol.2017.166215.
This Week's Must Reads
Must Reads in AML
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.
T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51
Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7
Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release